Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

START Midwest, Grand Rapids

University of Chicago, Chicago

Oklahoma University Health Sciences Center, Oklahoma City

University of Texas Southwestern Medical Center, Dallas

South Texas Accelerated Research Therapeutics, LLC, San Antonio

University of Washington, Seattle